SXTP (60 Degrees Pharmaceuticals) EBITDA Margin % : -1,588.15% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. 60 Degrees Pharmaceuticals's EBITDA for the three months ended in Sep. 2024 was $-2.14 Mil. 60 Degrees Pharmaceuticals's Revenue for the three months ended in Sep. 2024 was $0.14 Mil. Therefore, 60 Degrees Pharmaceuticals's EBITDA margin for the quarter that ended in Sep. 2024 was -1,588.15%.

60 Degrees Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals EBITDA Margin % Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

-15.64

-87.50

-945.74

-561.81

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBITDA Margin %	Get a 7-Day Free Trial									8,311.76	-1,600.79	389.66	-3,327.20	-1,588.15

Competitive Comparison of 60 Degrees Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's EBITDA Margin % falls into.

60 Degrees Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

60 Degrees Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.427	/	0.254
	=	-561.81 %

60 Degrees Pharmaceuticals's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-2.144	/	0.135
	=	-1,588.15 %

60 Degrees Pharmaceuticals (NAS:SXTP) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

60 Degrees Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Executives

Geoffrey S Dow	director, 10 percent owner, officer: CEO and President	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Cheryl Xu	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Charles W Allen	director	1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc.	10 percent owner	824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Paul Field	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller	officer: Chief Financial Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc.	10 percent owner	200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith	officer: Chief Medical Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey	director	1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036